NCT04611789View on ClinicalTrials.gov

A Study of LY3832479 (LY-CoV016) in Healthy Participants 1

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

February 10, 2021

Study Completion Date

February 10, 2021

Conditions
Healthy
Interventions
DRUG

LY3832479

Administered subcutaneously

DRUG

Placebo

Administered subcutaneously

Trial Locations (1)

32117

Covance Clinical Research Inc, Daytona Beach

All Listed Sponsors
collaborator

Shanghai Junshi Bioscience Co., Ltd.

OTHER

lead

Eli Lilly and Company

INDUSTRY

NCT04611789 - A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 | Biotech Hunter | Biotech Hunter